1
|
Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B, Zhuang L, Hudak S, Rees DG, Goldberg D, Barton C, Chang L, Vainshtein I, Liang M, Iciek L, Ambery P, Peakman M, Vaughan TJ, Tree TIM, Sansom DM, Bowen MA, Minter RR, Jermutus L. A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding. J Immunol 2017; 198:528-537. [PMID: 27881707 DOI: 10.4049/jimmunol.1600682] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Accepted: 10/13/2016] [Indexed: 12/16/2022]
Abstract
Affinity- and stability-engineered variants of CTLA4-Ig fusion molecules with enhanced pharmacokinetic profiles could yield improved therapies with the potential of higher efficacy and greater convenience to patients. In this study, to our knowledge, we have, for the first time, used in vitro evolution to simultaneously optimize CTLA4 affinity and stability. We selected for improved binding to both ligands, CD80 and CD86, and screened as dimeric Fc fusions directly in functional assays to identify variants with stronger suppression of in vitro T cell activation. The majority of CTLA4 molecules showing the largest potency gains in primary in vitro and ex vivo human cell assays, using PBMCs from type 1 diabetes patients, had significant improvements in CD80, but only modest gains in CD86 binding. We furthermore observed different potency rankings between our lead molecule MEDI5265, abatacept, and belatacept, depending on which type of APC was used, with MEDI5265 consistently being the most potent. We then created fusions of both stability- and potency-optimized CTLA4 moieties with human Fc variants conferring extended plasma t1/2 In a cynomolgus model of T cell-dependent Ab response, the CTLA4-Ig variant MEDI5265 could be formulated at >100 mg/ml for s.c. administration and showed superior efficacy and significantly prolonged serum t1/2 The combination of higher stability and potency with prolonged pharmacokinetics could be compatible with very infrequent, s.c. dosing while maintaining a similar level of immune suppression to more frequently and i.v. administered licensed therapies.
Collapse
Affiliation(s)
| | | | | | - Blagoje Soskic
- Royal Free Campus, Institute of Immunity and Transplantation, University College London, London NW3 2PF, United Kingdom
| | - Shereen Sabbah
- Department of Immunobiology, King's College London, London SE1 9RT, United Kingdom
- Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, United Kingdom
- National Institutes of Health Research Biomedical Research Centre at Guy's and St. Thomas' National Health Service Foundation Trust, London SE1 9RT, United Kingdom; and
| | | | | | | | | | - Ben Kemp
- MedImmune, Cambridge CB21 6GH, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | - Mark Peakman
- Department of Immunobiology, King's College London, London SE1 9RT, United Kingdom
- Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, United Kingdom
- National Institutes of Health Research Biomedical Research Centre at Guy's and St. Thomas' National Health Service Foundation Trust, London SE1 9RT, United Kingdom; and
| | | | - Tim I M Tree
- Department of Immunobiology, King's College London, London SE1 9RT, United Kingdom
- Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, United Kingdom
- National Institutes of Health Research Biomedical Research Centre at Guy's and St. Thomas' National Health Service Foundation Trust, London SE1 9RT, United Kingdom; and
| | - David M Sansom
- Royal Free Campus, Institute of Immunity and Transplantation, University College London, London NW3 2PF, United Kingdom
| | | | | | | |
Collapse
|
2
|
Nebija D, Noe CR, Lachmann B. Charge heterogeneity study of a Fc-fusion protein, abatacept, using two-dimensional gel electrophoresis. Pharmazie 2015; 70:527-534. [PMID: 26380522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Medicinal products obtained by recombinant DNA technology are complex molecules and demonstrate a high degree of molecular heterogeneity. Charge heterogeneity and isoform pattern of this class of medicines, are parameters important for their quality, safety, and efficacy. In this study we report the application of two-dimensional gel electrophoresis (2-D electrophoresis) for the quality assessment, identification, charge heterogeneity and isoform pattern study of recombinant protein, CTLA4-Ig (abatacept), which has been selected as an example of the drug class, known as Fc-fusion proteins. In order to achieve an efficient separation of this complex analyte,2-D electrophoresis was optimized employing different experimental conditions regarding the selection of an immobilized pH gradient (IPG), sample pretreatment, presentation and detection procedure. Experimental datadocumented that 2-D electrophoresis is a suitable method for the assessment of identity, purity, structural integrity, isoform pattern and to monitor charge heterogeneity and post-translational glycosylation of the Fc-fusion protein, abatacept.
Collapse
|